These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 35861701)

  • 1. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
    Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
    Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
    Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
    Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.
    Babai S; Voisin AL; Bertin C; Gouverneur A; Le-Louet H
    Drug Saf; 2020 Feb; 43(2):111-117. PubMed ID: 31630381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse events caused by immune checkpoint inhibitors.
    Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
    J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Huang DD; Liao BC; Hsu WH; Yang CY; Lin YT; Wu SG; Tsai TH; Chen KY; Ho CC; Liao WY; Shih JY; Yu CJ; Yang JC; Cheng AL; Shen YC
    Oncology; 2024; 102(4):318-326. PubMed ID: 37778345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer type and histology influence cutaneous immunotherapy toxicities: a multi-institutional cohort study.
    Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
    Br J Dermatol; 2024 Jun; 191(1):117-124. PubMed ID: 38366637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
    Sibaud V
    Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
    Bhardwaj M; Chiu MN; Pilkhwal Sah S
    Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients.
    Tong J; Kartolo A; Yeung C; Hopman W; Baetz T
    Curr Oncol; 2022 Oct; 29(10):7953-7963. PubMed ID: 36290906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy.
    Tang K; Seo J; Tiu BC; Le TK; Pahalyants V; Raval NS; Ugwu-Dike PO; Zubiri L; Naranbhai V; Carrington M; Gusev A; Reynolds KL; LeBoeuf NR; Asgari MM; Kwatra SG; Semenov YR
    JAMA Dermatol; 2022 Feb; 158(2):189-193. PubMed ID: 35019948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
    Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.